K-Bio Heads to the U.S.… Cross-border, Nucor, and AI Change the Game
"While the technological capabilities of domestic pharmaceutical companies are excellent, they have not received sufficient investment from global pharmaceutical firms or venture capital ( VC ) firms. Cross-border VC models that enable our companies to attract U.S. investment and expand into the
LEARN MORE